(3R)-3-<(tert-Butyldimethylsilyl)oxy>pentanedioic acid 1-<(R)-mandelic acid> ester

We are (3R)-3-<(tert-Butyldimethylsilyl)oxy>pentanedioic acid 1-<(R)-mandelic acid> ester CAS:131466-61-0 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:(3R)-3-<(tert-Butyldimethylsilyl)oxy>pentanedioic acid 1-<(R)-mandelic acid> ester
CAS.NO:131466-61-0
Synonyms:(3R)-3-<(tert-Butyldimethylsilyl)oxy>pentanedioic acid 1-<(R)-mandelic acid> ester
(3R)-3-(TERT-BUTYLDIMETHYLSILYLOXY)GLUTARIC ACID 1-((R)-(-)-MANDELIC ACID ESTER)
(3R)-3-(Tert-Butyldimethylsilyloxy)Glutaric Acid -1-((R)-(-)-Mandelic Acid Ester
 
Physical and Chemical Properties:
Molecular Formula C19H28O7Si
Molecular Weight 396.50700
 
Specification:
Appearance:White crystalline powder
Assay:≥99.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Rosuvastatin calcium(CAS:147098-20-2).

(3R)-3-<(tert-Butyldimethylsilyl)oxy>pentanedioic acid 1-<(R)-mandelic acid> ester


Related News: There are however certain APIs that are unknown and so require additional substances that work in conjunction with the API to produce the required effect.(3-cloropropil) dietoxi (metil) silano CAS:13501-76-3 There are however certain APIs that are unknown and so require additional substances that work in conjunction with the API to produce the required effect.6-fluorohexan-1-ol CAS:373-32-0 Different cell types can be affected, although the most common finding in MDS is a shortage of red blood cells (anaemia). Patients with higher-risk MDS may progress to the development of acute leukaemia.Sebacato de bis (2,2,6,6-tetrametil-4-piperidilo) CAS:52829-07-9 Different cell types can be affected, although the most common finding in MDS is a shortage of red blood cells (anaemia). Patients with higher-risk MDS may progress to the development of acute leukaemia.Green Valley said it would launch the drug “very soon” in China. The company also aims to roll out a phase-3 clinical trial with sites in the United States, Europe and Asia in early 2020 to facilitate global regulatory approval of the drug.

Related Products
Product Name
Diethyl dipropylmalonate View Details
Ethyl 2-(2-formylaminothiazol-4-yl) glyoxylate View Details
2,5-Difluorobenzoic acid View Details
Pyridoxal-5-phosphate manufacturer 6-Hydroxy-2-naphthimidamide methanesulfonate salt manufacturer 5-Amino-2-fluoropyridine manufacturer tert-butyl 4-(6-nitropyridin-3-yl)piperazine-1-carboxylate manufacturer 2,3-Difluorophenylboronic acid manufacturer